An Introduction to Infectious Disease Modeling

Join ICON experts for an in-depth overview of infectious disease modeling with a focus on assessment of interventions and its challenges.

The nature of communicable diseases results in unique epidemiological characteristics that must be accounted for when considering the epidemiological, clinical, and economic consequences of interventions that modify transmission. These interventions clearly include vaccines, but also drug treatments that may reduce the duration of infectiousness.

This webinar outlines the unique epidemiological characteristics of communicable diseases and demonstrates how correctly accounting for these in clinical and economic assessments of interventions can capture the full value of these interventions. Some of the challenges faced when performing these analyses are also addressed.

Key Topics Include:

Understanding infectious disease modeling
Why infectious disease modeling is needed
Challenges associated with infectious disease modeling

Presenters:
Pragya Khurana, MPH, BS
Epidemiologist
Global Health Economics, Outcomes Research and Epidemiology
ICON

Richard Pitman, PhD
Lead Health Economist & Epidemiologist
Global Health Economics, Outcomes Research and Epidemiology
ICON

Marija Zivkovic-Gojovic, PhD
Senior Consultant
Global Health Economics, Outcomes Research and Epidemiology
ICON

Resources

Podcast Q&A: Infectious Disease Modeling

Watch Webinar

Related Content

Pharma can target ultra-rare conditions — the next step is financing them

As science has enabled care for previously untreatable, ultra-rare conditions, health systems and governments are struggling with ways of financing research and development of these therapies. What are the solutions when the science has progressed, but the economics haven't?

Endpoints at #DIA23

The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.